Investigational drug · Phase 3
Ficerafusp
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma.
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 29, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
6
Any phase or sponsor naming "Ficerafusp"
First trial start
2025
Jan 28, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Ficerafusp", any sponsor or status.
Conditions studied
As listed on its trial records.
- Metastatic Head and Neck Squamous Cell Carcinoma
- Recurrent Head and Neck Squamous Cell Carcinoma
Approved drugs for the same conditions: Head and neck cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "Ficerafusp" as an intervention, largest first.
- FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCCPivotal-lookingRecruiting
Bicara TherapeuticsIndustry
NCT06788990 · 650 participants (planned) · Start Jan 28, 2025 · Primary completion Apr 2028
Drug: Ficerafusp alfa; Pembrolizumab (KEYTRUDA®) and 1 more · For: Metastatic Head and Neck Squamous Cell Carcinoma; Recurrent Head and Neck Squamous Cell Carcinoma
Sites: Birmingham, Alabama; Phoenix, Arizona; La Jolla, California · 242 sites in all
Bicara TherapeuticsIndustry
NCT04429542 · 473 participants (planned) · Start Jun 1, 2020 · Primary completion Oct 31, 2027
Drug: BCA101; Pembrolizumab · For: Head and Neck Squamous Cell Carcinoma; Squamous Cell Carcinoma of Anal Canal; Colorectal Cancer and 8 more
Sites: La Jolla, California; Los Angeles, California; Sacramento, California · 21 sites in all
- A Study Evaluating Ficerafusp Alfa (BCA101) QW in Combination With Pembrolizumab vs Alternative Ficerafusp Alfa Dosing in 1L R or M HNSCCPivotal-lookingRecruiting
Bicara TherapeuticsIndustry
NCT07807163 · 160 participants (planned) · Start Sep 2026 · Primary completion Mar 2028
Drug: Ficerafusp alfa; Pembrolizumab (KEYTRUDA®) · For: Metastatic Head and Neck Squamous Cell Carcinoma; Recurrent Head and Neck Squamous Cell Carcinoma
Sites: Fort Myers, Florida; Orlando, Florida; St. Petersburg, Florida · 7 sites in all
- Phase II Study of Ficerafusp Alfa in Combination With Nivolumab in Patients With Platinum-refractory Head and Neck Squamous Cell CarcinomaPivotal-lookingRecruiting
Groupe Oncologie Radiotherapie Tete et CouAcademic, hospital or other
NCT07529873 · 131 participants (planned) · Start Mar 3, 2026 · Primary completion Apr 2030
Drug: Ficerafusp alfa; Nivolumab · For: Squamous Cell Carcinoma of Head and Neck (SCCHN)
Sites: Villejuif, France
- Ficerafusp Alfa, Pembrolizumab, and Stereotactic Body Radiotherapy (SBRT) for Head and Neck Squamous Cell Carcinoma (HNSCC)Not yet recruiting
Washington University School of MedicineAcademic, hospital or other
NCT07552558 · 45 participants (planned) · Start Nov 30, 2026 · Primary completion Jan 31, 2029
Drug: Pembrolizumab; Ficerafusp alfa · For: Head and Neck Squamous Cell Carcinoma; HPV-Negative Squamous Cell Carcinoma
Sites: St Louis, Missouri
Dana-Farber Cancer InstituteAcademic, hospital or other
NCT07465276 · 32 participants (planned) · Start Mar 26, 2026 · Primary completion Apr 30, 2028
Drug: Ficerafusp alfa; Pembrolizumab · For: Head and Neck Squamous Cell Carcinoma (HNSCC); Squamous Cell Carcinoma of the Head and Neck
Sites: Boston, Massachusetts · 2 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Immunotherapeutic strategies in HPV-positive and HPV-negative recurrent/metastatic oropharyngeal squamous cell carcinoma: From PD-1 blockade to EGFR-directed bispecifics and therapeutic HPV vaccines.
Di Bello A, Gili R, Falcicchia R, et al. · Crit Rev Oncol Hematol 2026
- Ficerafusp Alfa (BCA101) With Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Two-Year Results of an Expansion Cohort of a Phase I/Ib Trial.
Hanna GJ, Zandberg DP, Wong DJ, et al. · J Clin Oncol 2026
- Recent highlights and breakthroughs in immunotherapy for head and neck cancers.
Vuille JA, Szturz P · Curr Opin Oncol 2026
- Beyond EGFR inhibition in head and neck squamous cell carcinoma: Overcoming resistance mechanisms and novel therapeutic frontiers.
Carosi F, Filippini DM, Fabbri L, et al. · Crit Rev Oncol Hematol 2026
- Bridging EGFR/TGF-β Signaling to Bypass Resistance to Immune Checkpoint Blockade.
Choudhury NJ, Kothari A, Bestvina CM, et al. · Clin Cancer Res 2025
- Phase I Clinical Trial of the Bifunctional EGFR/TGF-β Fusion Protein Ficerafusp Alfa (BCA101) Alone and in Combination with Pembrolizumab for Advanced Solid Tumors.
Hernando-Calvo A, Carvajal RD, Paik PK, et al. · Clin Cancer Res 2025
Also in development for Metastatic Head and Neck Squamous Cell Carcinoma
- BalstilimabAGEN2034Phase 23 trials
ImmunoGenesis · Metastatic Prostate Cancer, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Pancreatic Cancer
- ZalifrelimabPhase 22 trials
ImmunoGenesis · Metastatic Prostate Cancer, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Pancreatic Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.